about
Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphateSolution Structure of a DNA Duplex Containing the Potent Anti-Poxvirus Agent CidofovirComparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitroIntravitreal crystalline drug delivery for intraocular proliferation diseases.Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.Alkoxyalkyl esters of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine are potent inhibitors of the replication of wild-type and drug-resistant human immunodeficiency virus type 1 in vitro.Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replicationMicelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate.Inhibition of HIV-1 by octadecyloxyethyl esters of (S)-[3-hydroxy-2-(phosphonomethoxy)propyl] nucleosides and evaluation of their mechanism of action.Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoestersIntraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.Synthesis of the 5-phosphono-pent-2-en-1-yl nucleosides: a new class of antiviral acyclic nucleoside phosphonates.Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in miceEvaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections.Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in miceAlkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivoAntischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.Antiviral evaluation of octadecyloxyethyl esters of (S)-3-hydroxy-2-(phosphonomethoxy)propyl nucleosides against herpesviruses and orthopoxviruses.Design and development of oral drugs for the prophylaxis and treatment of smallpox infection.Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.Phospholipid prodrug inhibitors of the HIV protease. Antiviral activity and pharmacokinetics in rats.Synthesis and Antiviral Evaluation of Octadecyloxyethyl Benzyl 9-[(2-Phosphonomethoxy)ethyl]guanine (ODE-Bn-PMEG), a Potent Inhibitor of Transient HPV DNA Amplification.Inhibition of herpesvirus replication by hexadecyloxypropyl esters of purine- and pyrimidine-based phosphonomethoxyethyl nucleoside phosphonates.Intraocular properties of an alkoxyalkyl derivative of cyclic 9-(S)-(3-hydroxyl-2-phosphonomehoxypropyl) adenine, an intravitreally injectable anti-HCMV drug in rabbit and guinea pig.Synthesis and antiviral evaluation of alkoxyalkyl-phosphate conjugates of cidofovir and adefovir.In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA.In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections.Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV.Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.Chloroquine treatment does not cause phospholipid storage by depleting rat liver lysosomes of acid phospholipase A.Intravitreal toxicology and therapeutic efficacy of the carboxymethyl ester of the 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA-O-Me), a novel lipid antiviral prodrug for intraocular drug delivery.Effect of amiodarone on the phospholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo.Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models.Intraocular pharmacokinetics of a crystalline lipid prodrug, octadecyloxyethyl-cyclic-cidofovir, for cytomegalovirus retinitis.Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand.Role of phospholipases in myocardial ischemia: effect of cardioprotective agents on the phospholipases A of heart cytosol and sarcoplasmic reticulum in vitro.Synthesis and antiviral activity of 3'-azido-3'-deoxythymidine triphosphate distearoylglycerol: a novel phospholipid conjugate of the anti-HIV agent AZT.
P50
Q24530586-F4057CFD-D060-4D02-A891-4D202D1C894BQ27666791-0C7B495D-4550-4A97-A5F3-7080D31D6CB4Q33804593-37CD8C0C-B738-4A09-B27B-298D8D9F8F8DQ33847455-993D2049-E17C-4FC3-95D9-B30578C1D90FQ34483696-79137FD2-A651-4EC9-A606-5B71F63B648BQ34973723-44B333E3-A617-4E0E-BED3-180F2222497EQ35116027-35B9EEC3-D19B-4D20-ADEA-5A60FA1B5A4BQ35164657-E7D7F1D4-5894-4194-A728-C5ECC3C6619EQ35215440-6B9038DE-032D-467B-9DE8-0BBE1BB1AF7CQ35260316-27E1F020-47AA-4DD4-9034-51F1DC693334Q35364463-2DAB05E5-F586-4618-9603-1FC935DE2309Q35547866-2D452776-29FD-4483-AA95-4212CF5BC7C2Q35636006-F3B25BE8-4F8D-44C6-9554-EC10AF225581Q35648048-108A87A7-DE21-4FBC-81AF-E39C61255044Q35664058-3D555806-D385-4213-90E0-B2F951F6C0E8Q35768296-B8195F15-F8B9-4A9C-A88B-D5E5D3DA0205Q36095046-B9566CE3-7F3F-4F53-97DA-9518131E7C98Q36295406-72461C08-33F6-46EB-ACEB-1B8F837172B7Q37247639-FC0282AA-DFF2-4DD9-9942-AAC597B9F06AQ37450784-8AC79B03-768F-44AA-8F9D-760E71EB73A7Q37456244-41554DD0-A993-4D1B-A680-621D83544A2BQ38477864-A63E1C8A-7D92-465A-8A7C-09DDF575CFB5Q38482641-D449310C-3219-4B39-9543-D16356840E30Q38571017-19D5C755-8DA5-4F7A-9F81-2791DB4ECF8AQ38726984-F1B6FB55-F604-4EAD-9DE8-A52D79668551Q39929713-78B05ABD-2623-4B62-9D53-26D3D937C5D9Q40075411-54684471-7B4B-414B-89AE-4D2FE825C1E4Q40157684-99D1F357-A589-4DD3-815B-C9D81487B9EFQ40191250-BF7F5278-D65B-433B-A231-B41B627E99BAQ40794956-11955375-97AF-48A5-A946-DE718EB5B1BFQ41087664-CA34A009-B795-4A33-A069-1805407C4148Q41097585-32812329-D0BF-4766-A615-DBA4978B6B2FQ41594579-BAFFD2FE-5985-4F1B-A05F-271F5809FA0AQ41687255-2223F2D5-6822-44E3-ACEA-043B7AA9F816Q41693038-3359765A-F280-4B73-807B-8537853086D9Q41862474-20DB9393-15F6-40C3-A63B-92D631DD2C94Q41878497-36799A1E-26AE-47B5-8BAA-0E344935A978Q41915115-B107E52D-7A5A-445F-838F-9E7F15E198AEQ41945680-41A2393B-4EC6-4469-B44F-90724AAF194DQ42283554-6014E721-775B-4050-ABA9-245AB1BFE6B8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Karl Y Hostetler
@ast
Karl Y Hostetler
@en
Karl Y Hostetler
@es
Karl Y Hostetler
@nl
type
label
Karl Y Hostetler
@ast
Karl Y Hostetler
@en
Karl Y Hostetler
@es
Karl Y Hostetler
@nl
prefLabel
Karl Y Hostetler
@ast
Karl Y Hostetler
@en
Karl Y Hostetler
@es
Karl Y Hostetler
@nl
P106
P1153
7006343963
P31
P496
0000-0002-1155-2885